Granted Patent
B2
US 12,653,836 · App. 18/003,753 · Granted Jun 16, 2026
Ketogenic diet and ketone supplementation for cancer therapy
Assignee:
The Trustees of Princeton University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are methods for treating cancer, particularly gastrointestinal cancers, such as pancreatic cancer and colon cancer, with chemotherapeutic agent(s) in subjects on a ketogenic diet or a ketone supplement or both.
Claims (20)
1 . A method for treating a pancreatic cancer in a subject in need thereof, comprising administering to the subject an effective amount of a chemotherapeutic regimen comprising:
gemcitabine, or a pharmaceutically acceptable salt thereof;
paclitaxel, or a pharmaceutically acceptable salt thereof, wherein the paclitaxel, or pharmaceutically acceptable salt thereof, is administered in albumin-bound form; and
cisplatin,
wherein the subject is on a ketogenic diet or a ketone supplement or both.
2 . The method of claim 1 , wherein the pancreatic cancer is metastatic.
3 . The method of claim 1 , wherein the subject is on a ketogenic diet but not a ketone supplement.
4 . The method of claim 1 , wherein the subject is on a ketone supplement but not a ketogenic diet.
5 . The method of claim 1 , wherein the subject is on a ketogenic diet and a ketone supplement.
6 . The method of claim 1 , wherein the chemotherapeutic regimen is administered once weekly for two consecutive weeks on a 21-day cycle, and is not administered during the third week of the 21-day cycle.
7 . The method of claim 6 , wherein the chemotherapeutic regimen is administered on days 1 and 8 of the 21-day cycle.
8 . The method of claim 1 , wherein:
about 1,000 mg/m 2 gemcitabine, or a pharmaceutically acceptable salt thereof, is administered to the subject per day;
about 125 mg/m 2 paclitaxel, or a pharmaceutically acceptable salt thereof, is administered to the subject per day; and
about 25 mg/m 2 cisplatin, or a pharmaceutically acceptable salt thereof, is administered to the subject per day.
9 . The method of claim 1 , wherein the ketogenic diet has a weight ratio of saturated fatty acids to unsaturated fatty acids of greater than 1.
10 . The method of claim 1 , wherein the ketogenic diet comprises fat, protein and, optionally, carbohydrate, and the weight ratio of fat to the sum of protein and carbohydrate is at least or about: 2, 3, 4, 5, 6, 7, 8, 9 or 10.
11 . The method of claim 1 , wherein the ketogenic diet contains less than 5% by weight carbohydrate.
12 . The method of claim 1 , further comprising maintaining the subject on the ketogenic diet, the ketone supplement or both.
13 . The method of claim 1 , further comprising instructing the subject to consume the ketogenic diet, the ketone supplement or both.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 13, 2023
From: RABINOWITZ, JOSHUA D.; YANG, LIFENG
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 062675/0797 →
Continuity (2)
Provisional Application
63052027
· Jul 15, 2020
References Cited (128)
US 6214875B1
· Yang
· 2001
[cited by applicant]
US 7569350B2
· Gocke et al.
· 2009
[cited by applicant]
CA 2140866C
· 2003
[cited by applicant]
CA 2688293A1
· 2008
[cited by applicant]
WO 9402108A1
· 1994
[cited by applicant]
WO 2006065735A1
· 2006
[cited by applicant]
WO 2012165345A1
· 2012
[cited by applicant]
WO 2012172411A1
· 2012
[cited by applicant]
WO 2014183047A1
· 2014
[cited by applicant]
Jameson et al. (JAMA Oncology, 2020, vol. 6, pp. 125-132) (Year: 2020).
[cited by examiner]
Shukla et al. (Cancer & Metabolism 2014, vol. 2, article 18) (Year: 2014).
[cited by examiner]
Funahashi, H. et al., Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth, Pancreas, 36(4): 353-62 (2008).
[cited by applicant]
Nicolaou, K.C. et al., Calicheamicin 911: A rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity, Angew Chem Intl Ed Engl, 33:183-186 (1994).
[cited by applicant]
Weikang, Z. et al., “Modulatory Effects of EPA and DHA on Proliferation and Apoptosis of Pancreatic Cancer Cells”, Journal of Huazhong University of Science and Technology, Medical Science, vol. 27, No. 5, pp. 547-550 (…
[cited by applicant]
Aminzadeh-Gohari, S., et al., “A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model”, 201…
[cited by applicant]
Anonymous Author: “NCT04631445: Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer”, Nov. 10, 2020 (Nov. 10, 2020), 5 pages.
[cited by applicant]
Antoch, G., et al., “Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT an…
[cited by applicant]
Barborka, C.J. “Ketogenic Diet Treatment of Epilepsy in Adults”, 1928, J. Am. Med. Assoc. 91, 73.
[cited by applicant]
Bates, M. “Kinetics of ketone body metabolism in fasted and diabetic rats”, 1971, Am. J. Physiol.-Leg. Content 221, 984-991.
[cited by applicant]
Birsoy, K., et al., “An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis”, Cell 162, 540-551, 2015.
[cited by applicant]
Blodgett, T.M., et al., “PET/CT: form and function”, Radiology 242, 360-385, 2007.
[cited by applicant]
Brooks, G.A. “The Science and Translation of Lactate Shuttle Theory”, Cell Metab. 27, 757-785, 2018.
[cited by applicant]
Caffa, I., et al., “Fasting-mimicking diet and hormone therapy induce breast cancer regression”, 2020, Nature 583, 620-624.
[cited by applicant]
De Groot, S., et al., “Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial”, Nat. Commun. 11, 3083, 2020.
[cited by applicant]
Dobin, A., et al., “STAR: ultrafast universal RNA-seq aligner”, Bioinformatics 29, 15-21, 2013.
[cited by applicant]
Draoui, N., et al., “Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments”, Dis. Model. Mech. 4, 727-732, 2011.
[cited by applicant]
Erkan, M., et al., “The role of stroma in pancreatic cancer: diagnostic and therapeutic implications”, Nat. Rev. Gastroenterol. Hepatol. 9, 454-467, 2012.
[cited by applicant]
Faubert, B., et al., “Lactate Metabolism in Human Lung Tumors”, Cell 171, 358-371.e9, 2017.
[cited by applicant]
Favaro, E., et al. “Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells”, Cell Metab. 16, 751-764, 2012.
[cited by applicant]
Furukawa K et al: “Investigating the effect of chemotherapy combined with ketogenic diet on stage IV colon cancer”, Journal of Clinical Oncology; 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 20…
[cited by applicant]
Gao, X., et al.,“Dietary methionine influences therapy in mouse cancer models and alters human metabolism”, Nature, Aug. 2019; 572 (7769): 397-401.
[cited by applicant]
García-Cañaveras, J.C., et al., “The Tumor Metabolic Microenvironment: Lessons from Lactate”, Cancer Res. 79, 3155-3162, 2019.
[cited by applicant]
Goodman, R.P., et al., “Hepatic NADH reductive stress underlies common variation in metabolic traits”, Nature 1-5, 2020.
[cited by applicant]
Hagihara, K., et al., “Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer”, Nutrients, 2020, 12(5) 1473, 12 pages.
[cited by applicant]
Hingorani, S.R., et al., “Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice”, Cancer Cell 7, 469-483, 2005.
[cited by applicant]
Hompland, T., et al., “Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients”, Cancer Res. 78, 4774-4785, 2018,.
[cited by applicant]
Hopkins, B.D., et al., “Suppression of insulin feedback enhances the efficacy of PI3K inhibitors”, Nature 560, 499-503, 2018.
[cited by applicant]
Hui, S., et al., “Glucose feeds the TCA cycle via circulating lactate”, Nature 551, 115-118, 2017.
[cited by applicant]
Hui, S., et al., “Quantitative Fluxomics of Circulating Metabolites”, Cell Metabolism, 32, 676-688, Oct. 6, 2020.
[cited by applicant]
Iyikesici, M., “Long-Term Survival Outcomes of Metabilocally Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pa…
[cited by applicant]
Jameson, G.S., et al. “A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer”, J. Clin. Oncol. 35, 341-341, 2017.
[cited by applicant]
Jameson, G.S., et al., “Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial”, JAMA Oncol. 6, 125, …
[cited by applicant]
Juweid, M.E., and Cheson, B.D. (2009). “Positron-Emission Tomography and Assessment of Cancer Therapy” (Massachusetts Medical Society).
[cited by applicant]
Kamphorst, J.J., “Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids”, 2013, Proc. Natl. Acad. Sci. 110, 8882-8887.
[cited by applicant]
Kanarek, N., et al., “Dietary modifications for enhanced cancer therapy”, Nature 579, 507-517, 2020.
[cited by applicant]
Koong, A.C., et al., “Pancreatic tumors show high levels of hypoxia”, Int. J. Radiat. Oncol. 48, 919-922, 2020.
[cited by applicant]
Korge, P., et al., “Increased reactive oxygen species production during reductive stress: The roles of mitochondrial glutathione and thioredoxin reductases”, Biochim. Biophys. Acta BBA—Bioenerg. 1847, 514-525, 2015.
[cited by applicant]
Lardinois, D., et al., “Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography”, N. Engl. J. Med. 348, 2500-2507, 2003.
[cited by applicant]
Li, B., et al., “RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome”, BMC Bioinformatics 12, 323, 16 pages, 2011.
[cited by applicant]
Love, M.I., et al., “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2”, Genome Biol. 15, 550, 2014.
[cited by applicant]
Lunt, S.Y., et al., “Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation”, Annu. Rev. Cell Dev. Biol. vol. 27 27, 441-464, 2011.
[cited by applicant]
Maddocks, O.D.K., et al., “Modulating the therapeutic response of tumours to dietary serine and glycine starvation”, Nature 544, 372-376, 2017.
[cited by applicant]
McGarry, J.D., et al., “Ketone Body Metabolism in the Ketosis of Starvation and Alloxan Diabetes”, J. Biol. Chem. 245, 4382-4390, 1970.
[cited by applicant]
Morscher, R.J., et al., “Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model”, PLOS One 10, e0129802, 2015.
[cited by applicant]
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/US2021/041783, “Ketogenic Diet and Ketone Supplementa…
[cited by applicant]
Olive, K.P., et al., “Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer”, Science 324, 1457-1461, 2009.
[cited by applicant]
Patgiri, A., et al., “An engineered enzyme that targets circulating lactate to alleviate intracellular NADH:NAD+ imbalance”, Nat. Biotechnol. 38, 309-313, 2020.
[cited by applicant]
Pérez-Escuredo, J., et al., “Monocarboxylate transporters in the brain and in cancer. Biochim. Biophys”, Acta BBA—Mol. Cell Res. 1863, 2481-2497, 2016.
[cited by applicant]
Poff, A., et al., “Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer”, Int. J. Cancer J. Int. Cancer 135, 1711-1720, 2014.
[cited by applicant]
Puchalska, P., et al., “Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics”, Cell Metab. 25, 262-284, 2017.
[cited by applicant]
Rabinowitz, J.D., et al., “Lactate: the ugly duckling of energy metabolism”, Nat. Metab. 2, 566-571, 2020.
[cited by applicant]
Roberts, M.N., et al., “A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice”, Cell Metab. 26, 539-546.e5, 2017.
[cited by applicant]
Shimazu, T., et al., “Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor”, Science 339, 211-214, 2013.
[cited by applicant]
Shukla, S.K., et al., “Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia”, Cancer Metab. 2, 18, 2014.
[cited by applicant]
Sullivan, L.B., et al., “Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells”, Cell 162, 552-563, 2015.
[cited by applicant]
Sullivan, M.R., et al., “Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability”, ELife 8, e44235, 2019.
[cited by applicant]
Tanner, L.B., et al., “Four Key Steps Control Glycolytic Flux in Mammalian Cells”, Cell Syst. 7, 49-62.e8, 2018.
[cited by applicant]
TeSlaa, T., et al., “The Source of Glycolytic Intermediates in Mammalian Tissues”, Cell Metab. S1550413120307282, 2021.
[cited by applicant]
Titov, D.V., et al., “Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio”, Science 352, 231-235, 2016.
[cited by applicant]
Von Hoff, D.D., et al. “Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine”, N. Engl. J. Med. 369, 1691-1703, 2013.
[cited by applicant]
Weber, D.D., Aminazdeh-Gohari, S., and Kofler, B. (2018). Ketogenic diet in cancer therapy. Aging 10, 164-165.
[cited by applicant]
Weber, D.D., et al., “Ketogenic diet in the treatment of cancer—Where do we stand?”, 2020, Mol. Metab. 33, 102-121.
[cited by applicant]
Wu, G.Y., et al., “The effect of ketone bodies on alanine and glutamine metabolism in isolated skeletal muscle from the fasted chick”, 1988, Biochem. J. 255, 139-144.
[cited by applicant]
Yang, L., et al., “Serine Catabolismeeds NADH when Respiration Is Impaired”, 2020, Cell Metab. 31, 809-821.e6.
[cited by applicant]
Zahra, A., et al., “Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials”, 2017, …
[cited by applicant]
Bar-Sagi, D. and Feramisco, J.R., Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by Ras proteins, Science, vol. 233; No. 4768; 1061-1068 (1986).
[cited by applicant]
Bradley, M.C. et al., “Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study,” British Journal of Cancer, vol. 102; 1415-1421 (2010).
[cited by applicant]
Chun, S.Y. et al., “Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1a and HIF-2a target genes,” Mol. Cancer, vol. 9; No. 293; 1-11 (2010).
[cited by applicant]
Commisso, C. et al., “Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells,” Nature, vol. 497; No. 7451; 633-637 (2013).
[cited by applicant]
Deberardinis, R.J. et al, Brick by brick: metabolism and tumor cell growth, Curr. Opin. Genet. Dev., 18(1):54-61 (2008).
[cited by applicant]
Degenhardt, K. & White, E., A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis, Clin. Cancer Res., 12(18):5298-5304 (2006).
[cited by applicant]
Degenhardt, K. et al, BAX and BAK mediate p53-independent suppression of tumorigenesis, Cancer Cell, (2):193-203 (2002).
[cited by applicant]
Gaglio, D. et al., Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth, Molecular Systems Biology, 7(523): 1-15 (2011).
[cited by applicant]
Gingras, A-C. et al, Regulation of translation initiation by FRAP/mTOR, Genes & Development 15:807-826 (2001).
[cited by applicant]
Green, C.D. and Olson, L.K., Modulation of palmitate-induced endoplasmic reticulum stress and apoptosis in pancreatic ß-cells by stearoyl-CoA desaturase and Elovi6, Am. J. Physiol Endocrinol Metab., 300: E640-E649 (2011…
[cited by applicant]
Guillou, H. et al, The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice, Prog Lipid Res, 49(2):186-199 (2010).
[cited by applicant]
Guo, J.Y., et al, Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis, Genes & Development, 25:460-470 (2011).
[cited by applicant]
Hardy, S. et al, Oleate Activates Phosphatidylinositol 3-Kinase and Promotes Proliferation and Reduces Apoptosis of MDA-MB-231 Breast Cancer Cells, Whereas Palmitate Has Opposite Effects, Cancer Research, 60: 6353-6358 …
[cited by applicant]
Hess, D. et al, Inhibition of StearoylCoA Desaturase Activity Blocks Cell Cycle Progression and Induces Programmed Cell Death in Luna Cancer Cells, PLOS One 5(6):e11394 (2010).
[cited by applicant]
Hu, Y. et al, K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis, Cell Research, 22(2):399-412 (2012).
[cited by applicant]
Igal, A.R., Roles of StearoylCoA Desaturase-1 in the Regulation of Cancer Cell Growth, Survival and Tumorigenesis, Cancers, 3: 2462-2477 (2011).
[cited by applicant]
Joyce, T. et al., A molecular signature for epithelial to mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis, Clin Exp Metastasis, 26(6):569-587 (2009).
[cited by applicant]
Kalaany, N.Y. and Sabatini, D.M., Tumours with PI3K activation are resistant to dietary restriction, Nature 458(7239): 725-732 (2009).
[cited by applicant]
Kamphorst et al., “Liquid Chromatography High Resolution Mass Spectrometry Analysis of Fatty Acid Metabolism,” Anal. Chem, vol. 83; 9114-9122 (2011).
[cited by applicant]
Kamphorst et al., “Ras-driven cancer cells can scavenge exogenous lipids to support their proliferation,” BMC Proceedings, vol. 6; 1-2 (2012).
[cited by applicant]
Kannan, R. et al., Dietary Control of Lipogenesis in vivo in Host Tissues and Tumors of Mice Bearing Ehrlich Ascites Carcinoma, Cancer Research, 40:4606-4611 (1980).
[cited by applicant]
Khwaja, A. et al, Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, The EMBO Journal, 16(10): 2783-2793 (1997).
[cited by applicant]
Kim, J-W. et al, HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia, Cell Metabolism,(3):177-185 (2006).
[cited by applicant]
Krypuy, M. et al, High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer, BMC Cancer, 6:295-307 (2006).
[cited by applicant]
Li, C. et al, Prevention of carcinogenesis and inhibition of breast cancer tumor burden by dietary stearate, Carcinogenesis, 32(8): 1251-8 (2011).
[cited by applicant]
Li, H. et al, High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias, J. Lipid Res., 49(1): 230-44 (2008).
[cited by applicant]
Lu, W. et al, Metabolomic analysis via reversed-phase ion-pairing liquid chromatography coupled to a stand alone orbitrap mass spectrometer, Anal. Chem., 82(8): 3212-3221 (2010).
[cited by applicant]
Luyimbazi, D. et al, Rapamycin regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer, Mol. Cancer Ther., 9(10):2770-2784 (2010).
[cited by applicant]
Mason, P. et al, SCD1 Inhibition Causes Cancer Cell Death by Depleting Mono-Unsaturated Fatty Acids, PLOS One, 7(3):e33823 (2012).
[cited by applicant]
Menendez, J.A. and Lupu, R., Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat Rev Cancer, 7(10):763-777 (2007).
[cited by applicant]
Metallo, C.M. et al, Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia, Nature, 481(7381):380-384 (2011).
[cited by applicant]
Miyazaki, M. et al, Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice, Biochem Biophys Res. Commun., 380(4): 818-822 (2009).
[cited by applicant]
Mullen, A.R. et al, Reductive carboxylation supports growth in tumour cells with defective mitochondria, Nature 481(7381):385-388 (2011).
[cited by applicant]
Nomura, D.K. et al., Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis, Cell, 140(1): 49-61 (2010).
[cited by applicant]
Papandreou, I. et al, HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption, Cell Metabolism, 3:187-197 (2006).
[cited by applicant]
Roongta et al., “Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy,” Mol. Cancer Res., vol. 9; 1551-1561 (2011).
[cited by applicant]
Santos, C. R. and Schulze, A., Lipid metabolism in cancer, the FEBS Journal minireview, 279: 2610-2623 (2012).
[cited by applicant]
Sasagawa, T. et al., Abnormal serum lysophospholipids in multiple myeloma patients, Lipids, 34(1):17-21 (1998).
[cited by applicant]
Schulze, A. and Harris, A.L., How cancer metabolism is tuned for proliferation and vulnerable to disruption, Nature, 491:364-373 (2012).
[cited by applicant]
Shaw, R.J. and Cantley, L.C., Ras, PI(3)K and mTOR signaling controls tumour cell growth, Nature, 441:424-430 (2006).
[cited by applicant]
Sheta, E.A. et al, Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways, Oncogene, 20:7624-7634 (2001).
[cited by applicant]
Therasse, P. et al., New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Inst…
[cited by applicant]
Vander Heiden, M.G. et al, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation, Science, 324(5930):1029-1033 (2009).
[cited by applicant]
White, E., “Exploiting the bad eating habits of Ras-driven Cancers,” Genes and Dev., vol. 27; 2065-2071 (2013).
[cited by applicant]
Wise, D.R. et al, Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of a-ketoglutarate to citrate to support cell growth and viability, Proc. Natl. Acad. Sci., 108(49):19611-19616 (2011).
[cited by applicant]
Yang, S. et al, Pancreatic cancers require autophagy for tumor growth, Genes & Development, 25:717-729 (2011).
[cited by applicant]
Ying, H. et al, Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism, Cell, 149(3): 656-670 (2012).
[cited by applicant]
Hagihara, K., et al., “Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer”, Nutrients, 2020, 12(5) 1473, with accompanying Supplementary Materials (25 pages).
[cited by applicant]